Published in final edited form as:

Exp Parasitol. 2009 July ; 122(3): 182–191. doi:10.1016/j.exppara.2009.03.014.

***Leishmania donovani* lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts**

Upasna Gaur¹, Melissa Showalter², Suzanne Hickerson², Rahul Dalvi¹, Salvatore J. Turco³, Mary E. Wilson^{1,*†}, and Stephen M. Beverley^{2,†}

¹ Departments of Internal Medicine, Epidemiology and Microbiology, University of Iowa and the Veterans Affairs Medical Center, Iowa City IA 52242 USA

² Department of Molecular Microbiology, Washington University School of Medicine, St. Louis MO 63110 USA

³ Department of Biochemistry, University of Kentucky Medical Center, College of Medicine, Lexington, 40536 USA

Abstract

Surface phosphoglycans such as lipophosphoglycan (LPG) or proteophosphoglycan (PPG) and glycosylinositol phospholipids (GIPLs) modulate essential interactions between *Leishmania* and mammalian macrophages. Phosphoglycan synthesis depends on the Golgi GDP-mannose transporter encoded by *LPG2*. *LPG2*-null (*lpg2*[−]) *L. major* cannot establish macrophage infections or induce acute pathology, whereas *lpg2*[−] *L. mexicana* retain virulence. *lpg2*[−] *L. donovani* has been reported to survive poorly in cultured macrophages but in vivo survival has not been explored. Herein we discovered that, similar to *lpg2*[−] *L. major*, *lpg2*[−] *L. donovani* promastigotes exhibited diminished virulence in mice, but persisted at consistently low levels. *lpg2*[−] *L. donovani* promastigotes could not establish infections macrophages and could not transiently inhibit phagolysosomal fusion. Furthermore, *lpg2*[−] promastigotes of *L. major*, *L. donovani* and *L. mexicana* were highly susceptible to complement mediated lysis. We conclude that phosphoglycan assembly and expression mediated by *L. donovani* *LPG2* are important for promastigote and amastigote virulence, unlike *L. mexicana* but similar to *L. major*.

Keywords

GIPL; glycosylinositol phospholipids; LPG; lipophosphoglycan; PPG; proteophosphoglycan; RP-10; Macrophage growth medium with RPMI and 10% FCS; PG; phosphoglycan

INTRODUCTION

All *Leishmania* spp. are covered by a complex glycocalyx throughout the infectious cycle, and glycoconjugates are thought to be important factors promoting their virulence (reviewed in refs. Turco 1990; Ferguson 1999; Turco et al. 2001; Naderer et al. 2004). The promastigote

*Address correspondence to: Mary Wilson, Department of Internal Medicine, University of Iowa, SW34-GH, 200 Hawkins Dr., Iowa City IA 52242 USA; phone 319-356-3169; fax 319-384-7208; E-mail: mary-wilson@uiowa.edu.

†These authors contributed equally to the work.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

glycocalyx is especially dense and contains high levels of phosphoglycans (PGs) comprised of polymeric [6Gal(β 1,4)Man(α 1-PO₄)-] disaccharide phosphate-based repeating units. The main structural distinction among PGs from various *Leishmania* spp. is the side chain sugar substitutions that branch off the disaccharide-phosphate backbone. Depending on the growth phase, the abundant promastigote surface glycolipid lipophosphoglycan (LPG) contains 15–30 PG repeating units, bearing an external capping oligosaccharide and anchored to the surface by a heptasaccharide glycosylphosphatidyl inositol anchor (reviewed in ref. Turco 1990). Proteophosphoglycans (PPGs) comprise a family of large proteins containing Ser-Thr rich regions to which the PG repeating units are covalently linked (reviewed in refs. Ilg 2000). Amastigotes lack significant LPG but retain PPG expression, and both stages express high levels of smaller glycosylinositol phospholipids (GIPLs) (Elhay et al. 1988; McConville et al. 1994). The GPI anchors of LPG and PPGs show varying degrees of structural identity or similarity to those of GIPLs and GPI-anchored proteins (reviewed in refs. Turco 1990; Ferguson et al. 1999; Turco et al. 2001; Naderer et al. 2004). Many studies have shown that purified (or synthetic) LPG, PPG and GIPLs have significant effects on parasite survival, attributed their ability to execute key steps of the infectious cycle such as suppression of host cell signaling and activation, and evasion of killing by activated complement (reviewed in refs. Descoteaux and Turco 1999; Naderer et al. 2004). However, one challenge to the interpretation of *in vitro* studies is that test glycoconjugate(s) are provided outside of the context of the parasite, leading to concerns about the effects of dosage and route of application (Beverley and Turco 1998). A further challenge is the fact that these PG-containing and GPI-anchored *Leishmania* glycoconjugates show varying extents of structural relatedness, raising concerns about their cross activity during *in vitro* assays.

A second approach to glycoconjugate function has thus been to generate mutants through either forward or reverse genetic approaches (Beverley and Turco 1998). Depending of the specific gene affected, individual or specific subsets of glycoconjugates can be defective in mutants. These living organisms permit assessment of glycoconjugate deficiency in the proper biological context. For example, *L. major lpgI*[−] mutants lack the galactofuranosyl transferase activity required for synthesis of the LPG core domain but other parasite surface components remain unchanged by this mutation (Sacks et al. 2000; Spath et al. 2000; Spath et al. 2003a). These LPG-deficient *L. major* exhibit increased susceptibility to complement- and oxidant-mediated toxicity, and show decreased survival in macrophage infections, although they retain the ability to suppress macrophage responses leading to NO and IL-12 production (Spath et al. 2000; Spath et al. 2003a; Spath et al. 2003b). As expected because LPG expression is greatly down-regulated in amastigotes (Turco and Sacks 1991; Moody et al. 1993), *lpgI*[−] *L. major* amastigotes are fully virulent (Spath et al. 2000).

The role of PGs, which constitute major portions of both LPG and PPGs, was first probed genetically through studies of the *lpg2*[−] mutants which lack the Golgi GDP-mannose transporter *LPG2* required for PG synthesis (Descoteaux et al. 1995; Ma et al. 1997; Spath et al. 2003b). Like *lpgI*[−] mutants, *L. major lpg2*[−] mutants show heightened defects in promastigote virulence, but unlike *lpgI*[−] mutants, they are unable to replicate as amastigotes in macrophages and/or cause acute pathology. Nonetheless, they persist indefinitely at a low level (Spath et al. 2003b) and they induce protective immunity in mice (Uzonna et al. 2004; Kebaier et al. 2006). The defect in *L. major lpg2*[−] amastigotes was attributed to the lack of PGs in this stage, the only known glycoconjugate synthetic defect in *lpg2*[−] amastigotes of *L. major*, *L. donovani* and *L. mexicana* (Descoteaux et al. 1995; Ilg et al. 2001; Goyard et al. 2003; Spath et al. 2003b), and. However, recent studies of *L. major* challenged this assumption, using a double mutant (*lpg5A*[−]/*lpg5B*[−]) lacking PGs through ablation of the UDP-Gal transporters encoded by *LPG5A* and *LPG5B* (Spath et al. 2004; Capul et al. 2007b; Capul et al. 2007a). Remarkably this mutant shows a virulence phenotype very similar to that of LPG-deficient *lpgI*[−] *L. major*, which affects only promastigote virulence whereas amastigotes retain

full virulence (Capul et al. 2007a). Thus the loss of amastigote virulence in the *L. major* *lpg2*⁻ mutant is probably not merely due to the absence of PGs. The lack of involvement of PGs in amastigote virulence agrees with results obtained with *lpg2*⁻ *L. mexicana* which, unlike *lpg2*⁻ *L. major*, retain amastigote virulence and induce disease despite the absence of PGs (Ilg et al. 2001).

In this work we focus on the role of *LPG2* in the virulence of *L. donovani*. Similar to *L. major*, *L. donovani* resides in a 'tight' as parasitophorous vacuole, which differs from the 'spacious' vacuole occupied by *L. mexicana* (Castro et al. 2006). Curiously, whereas the forward genetic complementation methodology was first developed and then applied to the identification of *LPG* synthetic genes in *LPG*-deficient mutants in this species (Ryan et al. 1993; Beverley and Turco 1998), the use of these *L. donovani* mutants for functional studies of virulence in animal infections was compromised by several factors. One was the use of heavy mutagenesis and the lack of sexual crossing to generate isogenic lines, which was solved by the use of targeted replacement methods (Spath et al. 2000). A second problem was the tendency of some *Leishmania* species and especially those causing visceral disease to rapidly lose virulence during *in vitro* culture.

Previous studies have shown that some strains of *lpg2*⁻ *L. donovani* are unable to establish infections in macrophages *in vitro* (Lodge et al. 2006). However, the ability of these strains to survive in animal hosts has not previously been reported. In this work we make use of the observation that virulence can be maintained in *L. donovani* lines adapted for cycling between growth as promastigotes and axenic amastigotes despite extensive *in vitro* culture (Goyard et al. 2003; Debrabant et al. 2004), and generated *lpg2*⁻ null mutants in such a strain, the LdBob line of *L. donovani* (Goyard et al. 2003). This mutant (and its complemented control line) has allowed us, for the first time, to study the role of *LPG2* in a virulent *L. donovani* background in survival in mice, and to compare the requirement with the contrasting observations reported in *L. major* and *L. mexicana*. The LdBob *lpg2*⁻ line additionally allowed us to confirm *lpg2*⁻ phenotypes previously described such as macrophage survival and transient inhibition of phagolysosomal fusion, and extend this to susceptibility to lysis by complement.

MATERIALS AND METHODS

Parasites

All strains studied were derivatives of the *L. donovani* strain 1S2D (MHOM/SD/62/1S-CL2D) clonal line LdBob, which were grown alternately as amastigotes and promastigotes in serum-containing medium specific for each form as described (Goyard et al. 2003). Amastigotes were cultivated at 37°C, 5% CO₂, and promastigotes were grown at 26°C. Parasites were converted between forms every 3 weeks.

Previously we described the homozygous *LPG2* knockout line (formally, $\Delta lpg2::HYG/\Delta::HYG$), referred to as *lpg2*⁻ in this work, and a complemented derivative bearing an episomal *LPG2* construct (formally, $\Delta lpg2::HYG/\Delta lpg2::HYG$ [pX63NEO-LPG2]), referred to as *lpg2*⁻/+*LPG2*(e) here (Goyard et al. 2003). An integrated version of the complemented line was generated as follows: first, the *L. donovani* *LPG2* gene was excised by *Xho*II digestion from pXG63HYG-LPG2 [strain B1544 (Descoteaux et al. 1995)], and inserted into either the *Sma*I or *Bgl*III sites of pIR1SAT, yielding the constructs pIR1SAT-LdLPG2(a) and pIR1SAT-LdLPG2(b) (strains B5041 and B5043, respectively). These constructs were digested with *Swa*I and the targeting fragment was isolated and introduced into *L. donovani* *lpg2*⁻ by electroporation (Robinson and Beverley 2003). Clonal lines expressing the transfected construct were identified following plating on M199 media containing 5 µg/ml nourseothricin. All transfectant lines [$\Delta lpg2::HYG/\Delta lpg2::HYG$ SSU:IR1SAT-LdLPG2(a) or LdLPG2(b), respectively] bear *LPG2* integrated into the ribosomal RNA locus, where they are stably

expressed at high levels from the rRNA promoter (Robinson and Beverley 2003). All lines showed good differentiation and similar levels of LPG expression, and are referred to here as *lpg2⁻/+LPG2(i)*.

Complement sensitivity

Complement sensitivity tests were performed as described (Spath et al. 2003a). Briefly, promastigotes in logarithmic or stationary phase growth were exposed to 2% fresh human serum for 30 min in the presence of propidium iodide, whose uptake by permeabilized cells was quantitated by flow cytometry.

Immunoblotting

Promastigote or amastigote proteins were separated on reducing 9% denaturing SDS polyacrylamide gels, transferred to Nytran, and blocked in 5% milk/PBS/0.01% Tween-20. Filters were incubated with the following antisera: CA7AE, specific for unsubstituted [6Gal (β 1,4)Man(α 1-PO₄)-] phosphoglycan repeats (Goyard et al. 2003); polyclonal antiserum generated in sheep to purified *L. chagasi* GP63 (1:10,000), or monoclonal antibody to α -tubulin (AB-1, 0.1 μ g/ml, Oncogene, San Diego, CA) (Yao et al. 2002).

Mannan purification and analysis

Leishmania mannans were extracted by chloroform:methanol:water extraction, and fluorophore labeled. Mannans were separated by fluorophore-assisted carbohydrate electrophoresis (FACE) as described (Capul et al. 2007a).

Animals

Female BALB/c mice (age 4–6 weeks) were purchased from Harlan Laboratories (Indianapolis, IN). Mice were infected with 10⁷ stationary phase parasites belonging to different lines intravenously through the tail vein. At specified time points, animals were euthanized, organs were removed, and parasite loads were determined microscopically from touch preparations and organ weights as described (Stauber 1958; Wilson et al. 1987). All animal procedures were approved by the University of Iowa and the Iowa City VA institutional animal care and use committees.

Murine and human macrophage infections

Bone marrow cells (BMMs) from BALB/c mouse femurs were cultured at 37°C, 5% CO₂ in RP-10 (RPMI with 10% heat-inactivated fetal calf serum, 2mM L-glutamine, 100 U of penicillin/ml, and 50 μ g of streptomycin/ml [GIBCO, Carlsbad, CA.]) containing 20% L929 cell culture supernatant (American Tissue Type Collection, Manassas, VA) as a source of macrophage colony-stimulating factor. After 7 to 9 days, differentiated adherent macrophages were detached with 2.5 mg trypsin/ml plus 1 mM EDTA (GIBCO) (Coligan et al. 2007).

Human mononuclear cells were isolated from the peripheral blood of normal healthy donors by density sedimentation in Ficoll-Hypaque (Sigma Chemical Co., St. Louis, MO). Monocytes were separated by adherence to six-well plates (flow cytometry) for 2 to 3 h at 37°C and 5% CO₂ in RP-10.

5.0×10^5 macrophages were allowed to adhere to coverslips in 24-well plates and infected with opsonized promastigotes or amastigotes at a multiplicity of infection (MOI) of 5:1 as described (Rodriguez et al. 2006). The infection was synchronized by centrifugation (3 min, 330 $\times$ g, 4 °C) and infected macrophages were incubated in 5% CO₂ at 37°C. Extracellular parasites were removed by rinsing macrophages 30 min post-infection. At each time point, coverslips were fixed and stained with Diff-Quik (Fisher Scientific).

Flow Cytometry

Promastigotes were incubated in 5 μ M carboxyfluorescein diacetate succinimidyl ester (CFSE) for 30 min in a 37°C water bath, washed, and suspended at 2×10^7 /ml in Hanks balanced salt solution as described (Chang et al. 2007). Adherent monocytes were infected with fluorescent promastigotes at a 5:1 MOI, synchronized by centrifugation, and incubated at 37°C, 5% CO₂ for 15 min. Five μ M of dihydroethidium (DHE, Molecular Probes) were added, and after an additional 10 min at 37°C, promastigotes were removed by rinsing and phagocytes were detached in citric saline (0.135 M KCl, 0.015 M Na citrate). Cells were fixed in 2% paraformaldehyde in phosphate-buffered saline (EMS, Hatfield, PA) and analyzed on a Becton Dickinson FACSCalibur equipped with a 488 nm argon laser (BD Biosciences, San Diego, CA). Fluorescence was monitored at 480/30 nm (CFSE) and 580/42 nm (DHE), and Ten thousand events were examined. Data were analyzed using Cell Quest or Flow Jo software (BD Biosciences).

Confocal microscopy

Five $\times 10^5$ macrophages on 12 mm coverslips were infected with promastigotes stained with carboxy-fluorescein diacetate succinimidyl ester (Chang et al. 2007). Lysosomes were pre-labeled by incubation of macrophages in 0.8 μ g of Mr 10,000 TRITC-conjugated dextran/ml (Molecular Probes) for 16 hrs, followed by a rinse and chase in RP-10 without dextran for an additional 30 min. At the time of infection the endosomal pathway was marked in positive control macrophages by addition of 10,000 Mr fluorescein-labelled dextran (Molecular Probes) at the time of “infection”. Infected or control cells were fixed in 2% paraformaldehyde (30 min), permeabilized in 0.2% Triton X-100 (15 min), incubated in 50 mM glycine (15 min), and blocked in 5% non-fat dry milk/PBS (30 min). Macrophages were incubated with 50:1 goat anti-LAMP-1 (Santa Cruz) followed by 200:1 Alexa fluor 647 (blue) donkey anti-goat Ig at room temperature for 1 h. After rinsing in PBS and mounting with Vectashield H-1000 (Vector Labs, Burlingame, CA), slides were examined on a Zeiss 510 laser scanning confocal microscope, and captured using the LSM 510 version 3.2 software. Microscopic studies were performed at the University of Iowa Central Microscopy Research Facility.

RESULTS

In vivo defect of *lpg2⁻* *L. donovani* in mouse infections

Previously we reported the generation and properties of an *lpg2⁻* mutant in the LdBob line of *L. donovani*, able to differentiate between the promastigote and amastigote stage *in vitro* when cultured under appropriate conditions (Goyard, et al., 2003), along with complemented derivatives where *LPG2* expression was restored by transfection with an episomal *LPG2* expression vector [*lpg2⁻*/+*LPG2(e)*]. BALB/c mice were infected i.v. with WT, *lpg2⁻*, or *lpg2⁻*/+*LPG2(e)* stationary phase *L. donovani*, and at appropriate times animals were euthanized and parasite loads were quantified by microscopy (Fig. 1). As observed previously, WT parasites multiplied most quickly in the livers (Fig. 1B), peaking at 4–6 weeks and declining thereafter, whereas infection began slowly but progressed in the spleens of infected animals (Kaye and Farrell, 2002, Wilson and Weinstock, 1996). In contrast, *lpg2⁻* infections showed considerably fewer parasites at all time points in both organs (Fig. 1). In the liver, *lpg2⁻* parasites were found at 4 % of WT at the peak of the infection at week 4 (Fig. 1). Similarly, in the spleen *lpg2⁻* parasites were present at 3.5 % of WT levels at week 10 of infection. Importantly, restoration of *LPG2* expression partially restored parasite replication in both livers and spleens [Fig. 1; *lpg2⁻*/+*LPG2(e)*], although the effect was variable in different experiments (compare Figs. 1A,B with a second experiment shown in Fig. 1C).

Survival of *lpg2⁻ L. donovani* in macrophages

Given the attenuation of *lpg2⁻ L. donovani* replication in mouse infections, we studied its survival in murine bone marrow macrophages. In these studies, WT stationary phase *L. donovani* enter macrophages successfully and after a slight decrease in numbers after 24 hr, replicated about 2-fold over the next ~72 hr (Fig. 2). In contrast, while *lpg2⁻ L. donovani* were taken up by macrophages at a similar level as WT (Fig. 2; 2 hr time point), they were rapidly destroyed with their numbers declining to less than 5.2 % of WT by 96 hr. However and unlike the mouse infections experiments, one of the control lines in which *LPG2* was restored on an extrachromosomal plasmid did not restore macrophage survival, i.e. the *lpg2⁻/+LPG2(e)* line was destroyed as efficiently as *lpg2⁻* (Fig. 2). This was similar to results obtained in another recent study which episomal vector-based rescue of another PG deficient mutant (lacking the Golgi UDP-Gal nucleotide sugar transporters encoded by the *LPG5A* and *LPG5B* genes) was observed in mouse but not macrophage infections (Capul et al. 2007a). There we found that restoration of PG synthesis using a strong integrating *LPG5A+LPG5B* expression vector fully restored both mouse and macrophage virulence. Thus we hypothesized that the lower levels episomal *LPG2* arising from the episomal expression vectors might account for the failure to rescue. This idea meshed well with our results with *lpg2⁻ L. donovani*, as previous data showed that the *lpg2⁻/+LPG2(e)* line did not fully restore LPG expression back to WT levels either (Goyard et al. 2003).

We therefore generated several new transfectant restoration lines termed *lpg2⁻/+LPG2(i)*, where *LPG2* expression was restored using a strong rRNA-integrating expression vector (pIR1SAT; Methods). These *lpg2⁻/+LPG2(i)* lines synthesized WT levels of LPG and/or PPG, in stationary phase promastigotes, tested both before (Fig. 3A) and subsequent to mouse infections (Fig. 4B), and in axenic amastigotes (Fig. 3B). Curiously, restoration of LPG synthesis was not identical to WT in level or pattern in log phase promastigotes (Fig. 3A). However, we deemed this acceptable since virulence studies were carried out with infectious stationary phase promastigotes, which appeared normal in PG expression. Mannan levels were similar in WT and *lpg2⁻ L. donovani* (Fig. 4A). In agreement with previous studies in *L. major* and *L. mexicana lpg2⁻*, GP63 levels were similar in WT, *lpg2⁻* and *lpg2⁻/+LPG2(i)* promastigotes (Fig. 4B).

In animal tests, the results with the *lpg2⁻/+LPG2(i)* line resembled the *lpg2⁻/+LPG2(e)* line in showing partial but significant rescue of the *lpg2⁻* phenotype (Fig. 1D). Now when tested in bone marrow macrophage infections, *lpg2⁻/+LPG2(i)* infected and replicated with kinetics indistinguishable from WT, whereas *lpg2⁻* and the *lpg2⁻/+LPG2(e)* lines entered but were rapidly destroyed as before (Fig. 2). These data established that the macrophage virulence defect of the *lpg2⁻* line was specifically attributable to the absence of *LPG2*. They also stress the importance of achieving full restoration of *LPG2* expression, in a form that is maintained in the absence of drug pressure, in the restoration lines.

lpg2⁻ mutants of all three *Leishmania* species are susceptible to lysis by complement

We assessed the susceptibility of logarithmic and infective stage stationary phase *lpg2⁻* mutants to lysis by complement (fresh human serum). Prior report of this assay indicates that lysis of *Leishmania* is mediated exclusively by complement (Spath et al. 2003a). Both growth phases of *lpg2⁻ L. donovani* were susceptible to complement under these conditions, as seen by their uptake of propidium iodide in the presence by not absence of serum, whereas WT *L. donovani* were not lysed (Fig. 5, bottom panels). These results were similar to those obtained with the *lpg2⁻ L. major* controls studied previously (Spath et al. 2003a) (Fig. 5, top panel). Interestingly, both growth phases of *lpg2⁻* but not WT *L. mexicana* promastigotes were highly susceptible to complement-mediated lysis (Fig. 5, middle panels). These data suggest that

LPG2 may similarly contribute to *L. mexicana* promastigote virulence by mediating resistance to lysis by complement in human serum, presumably through PG synthesis.

***L. donovani* *lpg2*⁻ induces a stronger respiratory burst**

We previously developed a flow cytometry-based method for measuring mononuclear phagocyte oxidative response to *L. chagasi* promastigote phagocytosis, following oxidation of dihydroethidium, which primarily detects the products of the NADPH oxidase (Chang et al. 2007). Application of this methodology here showed that *lpg2*⁻ *L. donovani* induced somewhat higher oxidant production than WT or *lpg2*⁻/*LPG2*(i) upon infection of human mononuclear phagocytes (1.7 fold; Fig. 6). These data suggest that PGs and/or other *LPG2*-dependent molecules may assist in limiting oxidant levels produced by phagocytes (Chan et al. 1989; Spath et al. 2003a).

***lpg2*⁻ *L. donovani* promastigotes are defective in their ability to delay phagolysosomal fusion**

Studies of *lpg1*⁻ and *lpg2*⁻ mutants *L. major* and *L. donovani* have shown that LPG is responsible for the transient delay in the ability of infective promastigotes to delay fusion of phagosomes with lysosomes (Desjardins and Descoteaux 1997; Dermine et al. 2000; Spath et al. 2003a; Spath et al. 2003b). To assess phagolysosomal fusion, we used confocal microscopy to assess the degree of overlapping parasite and lysosomal markers after phagocytosis by murine bone marrow macrophages (only the 2 hr time point is shown in Fig. 7). As previously reported, the ability to delay phagosome-lysosome fusion was greatly reduced in *lpg2*⁻ promastigotes, but returned to WT levels following restoration of *LPG2* expression (Fig. 7, Fig. 8).

DISCUSSION

In this study we explored the effects of *LPG2* ablation on the virulence of *L. donovani*, a parasite causing human visceral leishmaniasis in the Old World. Using mutants on the LdBob strain background, our studies confirm earlier reports that *lpg2*⁻ *L. donovani* are deficient in PG-containing glycoconjugates (Descoteaux et al. 1995), resulting in a defect in its ability to delay phagosome-lysosome fusion, and a failure to replicate in isolated macrophages (Lodge and Descoteaux 2005; Lodge et al. 2006). Importantly, our work extends these observations by providing the key biological finding that *lpg2*⁻ promastigotes induce very low levels of infection in spleens and livers of mice. These results indicate that the virulence phenotype of *lpg2*⁻ *L. donovani* is more similar to *L. major* and unlike *L. mexicana*, and may contribute to our understanding of the mechanism of persistence.

Our studies show that the virulence defects of the *lpg2*⁻ *L. donovani* were specific, as restoration of *LPG2* expression to the *lpg2*⁻ mutant fully or partially restored virulence in the tests performed. Curiously, while restoration of *LPG2* expression by either episomal or integrating expression vectors yielded similar partial restoration of virulence in animal infections (Fig. 1), only the integrated *LPG2* rescue line (*lpg2*⁻/*LPG2*(i) showed restoration of macrophage survival when tested in BMMs *in vitro* (Fig. 2). This was similar to results obtained in another recent study in which episomal vector-based rescue of another PG deficient mutant (lacking the Golgi UDP-Gal nucleotide sugar transporters encoded by the *LPG5A* and *LPG5B* genes) was observed in mouse but not macrophage infections (Capul et al. 2007a). As in that study, we found that integration of *LPG2* into the ribosomal RNA locus resulted in a more complete restoration of glycoconjugate expression (Fig. 3). Thus for some reason the *in vitro* macrophage assay is more sensitive to the imperfect re-expression of *LPG2* whereas the mouse assay, in which expression is allowed over a longer period of time, allows differences between knockout and add-back to emerge. It remains to be seen the exact reason for these differences.

Our findings emphasize some of the challenges posed by virulence tests in *Leishmania*. First and as indicated above, available *Leishmania* expression vectors lead to over-expression of *LPG2* from multicopy episomes or at still higher levels following integration into the rRNA locus ((Kapler et al. 1990; Misslitz et al. 2000). A similar previous study of the HSP100 gene (Hubel et al. 1997) showed that *Leishmania major* Hsp100 is required chiefly in the mammalian stage of the parasite, and that over expression can be deleterious in various ways. Perhaps *LPG2* when highly overexpressed in *L. donovani* is detrimental to virulence *in vivo*, although this phenomenon was not seen with studies of *LPG2* in *L. major* (Spath, et al., 2003 b). Second, some variation in virulence restoration may be attributable to the well known tendency of these parasites to lose virulence during culture and/transfection (Cruz et al. 1993), rendering some transfectants less virulent for this reason rather than the intended genetic manipulation. Thus we and other investigators have adopted the operational criterion that successful restoration of virulence may nonetheless sometimes be incomplete or variable amongst different clonal transfectants, for the reasons cited above. Thus because of the tendency of *Leishmania* to lose virulence spontaneously, when examining independent clonal lines, negative results are meaningless, as long as one is able to achieve a successful phenotypic rescue with at least some of them.

Given the similar biochemical consequences of *LPG2* ablation between *L. major*, *L. donovani* and *L. mexicana*, it is not immediately evident why the effects on virulence differ so greatly between *L. major/L. donovani* versus *L. mexicana*. These findings emphasize the well known concept that virulence determinants often play different roles in different stages of pathogens with complex life cycles. One possible explanation is that there could be as yet undetected differences in the *LPG2*-dependent glyco-repertoire between these species. Whereas abundant *Leishmania* glycoconjugates have been extensively studied, potentially less abundant but functionally active molecules could remain to be discovered. Indeed, a similar explanation has been advanced to account for the fact that PG-deficient *L. major* mutants generated through ablation of the UDP-Gal transporters *LPG5A* and *LPG5B* show normal virulence as amastigotes, although they remain attenuated as promastigotes like *lpg1⁻* and *lpg2⁻* mutants (Capul et al. 2007a).

A second explanation to account for the differences between *L. major/L. donovani* and *L. mexicana* invokes fundamental differences in the nature of the parasitophorous vacuole inhabited by the parasites. The parasitophorous vacuole harboring intracellular *L. mexicana* is relatively 'spacious', and typically houses multiple organisms, whereas the parasitophorous vacuoles occupied by *L. major* and *L. donovani* are considered to be 'tight', with the parasite and host membranes in close proximity, and typically housing only a single organism (Castro et al. 2006). It is possible that the species specific differences in parasite survival reflect different interactions of LPG and/or other *LPG2*-dependent metabolites with these two types of vacuoles. Indeed, there are several studies which suggest that the fusogenicity of the vacuole differs between the *Leishmania* species (Courret et al. 2002). As the effects of LPG on fusion of the *L. mexicana* vacuole has been less studied than the *L. donovani* vacuole, more specific hypotheses cannot yet be drawn.

Parasitophorous vacuoles harboring virulent *L. donovani* promastigotes show a transiently decreased ability to fuse with lysosomes for a period of up to 24 hr following infection. Studies of *lpg1⁻* *L. donovani* and *L. major* in the literature suggest this effect is mediated exclusively by LPG, according to studies with *lpg1⁻* mutants which specifically lack LPG but retain PPGs and other known glycoconjugates (Dermine et al. 2000; Spath et al. 2003a). As predicted, the LPG-deficient *lpg2⁻* *L. donovani* studied here was impaired in its ability to inhibit phagolysosomal fusion (Figs. 7, 8). Amastigotes, in contrast to promastigotes, lack LPG and reside within highly fusogenic vacuoles (Alexander and Russell 1992; Lang et al. 1994; Naderer et al. 2004).

The functional consequences of LPG-dependent transient phagolysosomal fusion inhibition may be multifold. Initial studies assumed the delay served merely to provide sufficient time for promastigotes to differentiate into amastigotes (Desjardins and Descoteaux 1997). However, mechanistic studies of the *lpg1*⁻ mutants showed a delay in fusion does not necessarily promote parasite survival (Spath et al. 2003a). Recent studies suggest that LPG alters phagolysosomal biogenesis profoundly, one consequence of which in *L. donovani* infections is the formation of a periphagosomal barrier of F-actin which hinders the ability of the NADPH oxidase to assemble on the phagocyte membrane (Dermine et al. 2005; Lodge and Descoteaux 2005; Lodge et al. 2006). Consistently, stationary phase WT induce significant levels of oxidants, but the levels are heightened during infection with LPG-deficient mutants (Fig. 6). Transient inhibition of phagolysosome fusion presumably allows the parasite to avoid exposure to physically separate itself from toxic lysosomal contents. Inhibition may also play a role in other processes, for example in modulating early interactions of macrophages with other arms of the immune system (Lodge and Descoteaux 2005). The summation of lower oxidant generation, residence in an unfused vacuole surrounded by an actin barrier that may prevent access of oxidants, and resistance to oxidant-mediated toxicity conferred by the LPG and PPGs of WT promastigotes (Spath et al. 2003a; Lodge et al. 2006) likely accounts for the lowered survival of *lpg2*-compared to WT *L. donovani* in host macrophages. The reciprocal relationship of LPG and the oxidative stress may have been even more remarkable if the infectious metacyclic forms of WT promastigotes had been used, since their LPGs contain approximately twice the number of the oxidant-scavenging repeating units compared to procyclic promastigote LPGs (Chan et al. 1989). There is unfortunately no method that could obtain metacyclic *lpg2*- parasites comparable to this control.

Previous studies implicated LPG as a major determinant promoting parasite resistance to lysis by complement. There are important differences between the lytic arm of the complement pathway in murine versus human hosts, with serum from the former exhibiting considerably weaker lytic activity than in other mammals (Ong and Mattes 1989). Thus while sensitive to lysis by human complement, LPG-deficient *Leishmania* are resistant to lysis by murine complement, and no alterations in the course of *L. major* infection are seen in comparisons between C5-deficient and normal mice (Spath et al. 2003a). During the current study, we showed for the first time that as expected *lpg2*⁻ *L. donovani* was exquisitely sensitive to complement-mediated lysis (Fig. 5). Furthermore and despite its lack of *in vivo* attenuation in mouse models, the *L. mexicana lpg2*⁻ mutant was similarly susceptible to lysis by human complement. Because of the differences between complement of mice and humans, it is possible that the sensitivity of *lpg2*⁻ mutants is of little consequence in mouse infections, whereas in human hosts the complement susceptibility of *lpg2*⁻ mutant promastigotes of all three species of *Leishmania* could result in attenuation.

In summary, our studies emphasize several important differences in the effects of LPG2 on the virulence of three *Leishmania* species, revealing an unexpected complexity and divergence in outcomes. We have focused in this work on the consequences for virulence as measured by parasite replication and/or pathology. Future studies may focus on immune responses to WT vs. *lpg2*⁻ *L. donovani* in comparison to WT vs. *lpg2*⁻ *L. major* (Uzonna et al. 2004; Kebaier et al. 2006). It may be of interest to perform quantitative comparisons of *L. major* and *L. donovani lpg2*⁻ mutant infections. If the numbers of persistent *lpg2*⁻ *L. donovani* are indeed greater than *lpg2*⁻ *L. major* footpads (typically ~10³) as suggested in Figure 1 (>10⁸ and >10⁶ in liver and spleen, respectively) (typically ~10³; Spath et al. 2003b; Spath et al. 2004), this could reflect differences in the infected cell types and/or the size or cell numbers between these organs and footpad infection sites. Alternatively, this could reflect fundamental differences between the biology of the two parasite species, manifesting *in vivo* but less apparent in macrophage infections *in vitro* (Fig. 2). These studies will have some practical value, as parasites showing 'persistence without pathology' such as *lpg2*⁻ *L. major* and *L.*

donovani hold promise as live attenuated vaccine lines (Spath et al. 2003b; Uzonna et al. 2004).

Acknowledgments

This work is supported in part by NIH grants AI045540 and AI067874 (MEW), a VA Merit Review grant (MEW), NIH grant AI31078 (SMB and SJJ), and NIH training grants T32 AI07511 and T32 AI007260-22 (support of UG). We thank Tamara Barron for technical assistance and members of our laboratories for discussions. The authors are also grateful to Jian Shao at the University of Iowa Central Microscopy Facility for technical assistance.

References

1. Alexander J, Russell DG. The interaction of *Leishmania* species with macrophages. *Advances in Parasitology* 1992;31:175–254. [PubMed: 1496927]
2. Beverley SM, Turco SJ. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite *Leishmania*. *Trends in Microbiology* 1998;6(1):35–40. [PubMed: 9481823]
3. Capul AA, Hickerson S, Barron T, Turco SJ, Beverley SM. Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in *Leishmania major*. *Infection and Immunity* 2007a;75(9):4629–4637. [PubMed: 17606605]
4. Capul AA, Barron T, Dobson DE, Turco SJ, Beverley SM. Two functionally divergent UDP-Gal nucleotide sugar transporters participate in phosphoglycan synthesis in *Leishmania major*. *The Journal of Biological Chemistry* 2007b;282(19):14006–14017. [PubMed: 17347153]
5. Castro R, Scott K, Jordan T, Evans B, Craig J, et al. The ultrastructure of the parasitophorous vacuole formed by *Leishmania major*. *The Journal of Parasitology* 2006;92(6):1162–1170. [PubMed: 17304790]
6. Chan J, Fujiwara T, Brennan P, McNeil M, Turco SJ, et al. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. *Proceedings of the National Academy of Sciences of the United States of America* 1989;86:2453–2457. [PubMed: 2538841]
7. Chang HK, Thalhofer C, Duerkop BA, Mehling JS, Verma S, et al. Oxidant generation by single infected monocytes after short-term fluorescence labeling of a protozoan parasite. *Infection and Immunity* 2007;75(2):1017–1024. [PubMed: 17118986]
8. Coligan, JE.; Kruisbeek, AM.; Margulies, DH.; Shevach, EM.; Strober, W., et al. *Current Protocols in Immunology*. New York: John Wiley and Sons; 2007.
9. Courret N, Frehel C, Gouhier N, Pouchelet M, Prina E, et al. Biogenesis of *Leishmania*-harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. *Journal of Cell Science* 2002;115(Pt 11):2303–2316. [PubMed: 12006615]
10. Cruz AK, Titus R, Beverley SM. Plasticity in chromosome number and testing of essential genes in *Leishmania* by targeting. *Proceedings of the National Academy of Sciences of the United States of America* 1993;90(4):1599–1603. [PubMed: 8381972]
11. Debrabant A, Joshi MB, Pimenta PF, Dwyer DM. Generation of *Leishmania donovani* axenic amastigotes: their growth and biological characteristics. *International Journal for Parasitology* 2004;34(2):205–217. [PubMed: 15037106]
12. Dermine JF, Scianimanico S, Prive C, Descoteaux A, Desjardins M. *Leishmania* promastigotes require lipophosphoglycan to actively modulate the fusion properties of phagosomes at an early step of phagocytosis. *Cellular Microbiology* 2000;2(2):115–126. [PubMed: 11207568]
13. Dermine JF, Goyette G, Houde M, Turco SJ, Desjardins M. *Leishmania donovani* lipophosphoglycan disrupts phagosome microdomains in J774 macrophages. *Cellular Microbiology* 2005;7(9):1263–1270. [PubMed: 16098214]
14. Descoteaux A, Turco SJ. Glycoconjugates in *Leishmania* infectivity. *Biochim Biophys Acta* 1999;1455(2–3):341–352. [PubMed: 10571023]
15. Descoteaux A, Luo Y, Turco SJ, Beverley SM. A specialized pathway affecting virulence glycoconjugates of *Leishmania*. *Science (New York, NY)* 1995;269:1869–1872.

16. Desjardins M, Descoteaux A. Inhibition of phagolysosomal biogenesis by the *Leishmania* lipophosphoglycan. *Journal of Experimental Medicine* 1997;185(12):2061–2068. [PubMed: 9182677]
17. Elhay MJ, McConville MJ, Handman E. Immunochemical characterization of a glyco-inositol-phospholipid membrane antigen of *Leishmania major*. *Journal of Immunology* 1988;141(4):1326–1331.
18. Ferguson MA. The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. *Journal of cell science* 1999;112 (Pt 17):2799–2809. [PubMed: 10444375]
19. Ferguson MA, Brimacombe JS, Brown JR, Crossman A, Dix A, et al. The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. *Biochim Biophys Acta* 1999;1455(2–3):327–340.
20. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, et al. An *in vitro* system for developmental and genetic studies of *Leishmania donovani* phosphoglycans. *Molecular and Biochemical Parasitology* 2003;130(1):31–42. [PubMed: 14550894]
21. Hubel A, Krobitsch S, Horauf A, Clos J. *Leishmania major* Hsp100 is required chiefly in the mammalian stage of the parasite. *Molecular and Cellular biology* 1997;17(10):5987–5995. [PubMed: 9315657]
22. Ilg T. Proteophosphoglycans of *Leishmania*. *Parasitology today (Personal ed)* 2000;16(11):489–497. [PubMed: 11063860]
23. Ilg T, Demar M, Harbecke D. Phosphoglycan repeat-deficient *Leishmania mexicana* parasites remain infectious to macrophages and mice. *The Journal of Biological Chemistry* 2001;276(7):4988–4997. [PubMed: 11071892]
24. Kapler GM, Coburn CM, Beverley SM. Stable transfection of the human parasite *Leishmania major* delineates a 30-kilobase region sufficient for extrachromosomal replication and expression. *Molecular and Cellular Biology* 1990;10(3):1084–1094. [PubMed: 2304458]
25. Kebaier C, Uzonna JE, Beverley SM, Scott P. Immunization with persistent attenuated $\Delta lpg2$ *Leishmania major* parasites requires adjuvant to provide protective immunity in C57BL/6 mice. *Infection and Immunity* 2006;74(1):777–780. [PubMed: 16369039]
26. Lang T, Hellio R, Kaye PM, Antoine JC. *Leishmania donovani*-infected macrophages: characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation. *Journal of cell science* 1994;107:2137–2150. [PubMed: 7983173]
27. Lodge R, Descoteaux A. Modulation of phagolysosome biogenesis by the lipophosphoglycan of *Leishmania*. *Clinical Immunology* 2005;114(3):256–265. [PubMed: 15721836]
28. Lodge R, Diallo TO, Descoteaux A. *Leishmania donovani* lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. *Cellular Microbiology* 2006;8(12):1922–1931. [PubMed: 16848789]
29. Ma D, Russell DG, Beverley SM, Turco SJ. Golgi GDP-mannose uptake requires *Leishmania* LPG2. A member of a eukaryotic family of putative nucleotide-sugar transporters. *Journal of Biological Chemistry* 1997;272(6):3799–3805. [PubMed: 9013638]
30. McConville MJ, Schneider P, Proudfoot L, Masterson C, Ferguson MA. The developmental regulation and biosynthesis of GPI-related structures in *Leishmania* parasites. *Brazilian Journal of Medical Biology Research* 1994;27:139–144.
31. Misslitz A, Mottram JC, Overath P, Aebischer T. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in *Leishmania* amastigotes. *Molecular and biochemical parasitology* 2000;107(2):251–261. [PubMed: 10779601]
32. Moody SF, Handman E, McConville MJ, Bacic A. The structure of *Leishmania major* amastigote lipophosphoglycan. *The Journal of Biological Chemistry* 1993;268:18457–18466. [PubMed: 8360147]
33. Naderer T, Vince JE, McConville MJ. Surface determinants of *Leishmania* parasites and their role in infectivity in the mammalian host. *Current Molecular Medicine* 2004;4(6):649–665. [PubMed: 15357214]
34. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. *Journal of Immunological Methods* 1989;125(1–2):147–158. [PubMed: 2607149]

35. Robinson KA, Beverley SM. Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite *Leishmania*. *Molecular and Biochemical Parasitology* 2003;128(2):217–228. [PubMed: 12742588]
36. Rodriguez NE, Gaur U, Wilson ME. Role of caveolae in *Leishmania chagasi* phagocytosis and intracellular survival in macrophages. *Cellular Microbiology* 2006;8(7):1106–1120. [PubMed: 16819964]
37. Ryan KA, Garraway LA, Descoteaux A, Turco SJ, Beverley SM. Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of *Leishmania*. *Proceedings of the National Academy of Sciences of the United States of America USA* 1993;90:8609–8613.
38. Sacks DL, Modi G, Rowton E, Spath G, Epstein L, et al. The role of phosphoglycans in *Leishmania*-sand fly interactions. *Proceedings of the National Academy of Sciences of the United States of America* 2000;97(1):406–411. [PubMed: 10618431]
39. Spath GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of *Leishmania major* infections in mammalian hosts. *Proceedings of the National Academy of Sciences of the United States of America* 2003a;100(16):9536–9541. [PubMed: 12869694]
40. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of *Leishmania major* able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. *Infection and Immunity* 2004;72(6):3622–3627. [PubMed: 15155672]
41. Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, et al. Persistence without pathology in phosphoglycan-deficient *Leishmania major*. *Science (New York, NY)* 2003b;301(5637):1241–1243.
42. Spath GF, Epstein L, Leader B, Singer SM, Avila HA, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite *Leishmania major*. *Proceedings of the National Academy of Sciences of the United States of America* 2000;97(16):9258–9263. [PubMed: 10908670]
43. Stauber LA. Host resistance to the Khartoum strain of *Leishmania donovani*. *Rice Institute Pamphlets* 1958;45:80–96.
44. Tolson DL, Turco SJ, Beecroft RP, Pearson TW. The immunochemical structure and surface arrangement of *Leishmania donovani* lipophosphoglycan determined using monoclonal antibodies. *Molec Bioch Parasitology* 1989;35:109–118.
45. Turco SJ. The leishmanial lipophosphoglycan: a multifunctional molecule. *Experimental Parasitology* 1990;70:241–245. [PubMed: 2404784]
46. Turco SJ, Sacks DL. Expression of a stage-specific lipophosphoglycan in *Leishmania major* amastigotes. *Molecular and biochemical parasitology* 1991;45:91–99. [PubMed: 1646960]
47. Turco SJ, Späth GF, Beverley SM. Is lipophosphoglycan a virulence factor? A surprising diversity between *Leishmania* species. *Trends in Parasitology* 2001;17(5):223–226. [PubMed: 11323305]
48. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient *Leishmania major* protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. *Journal of Immunology* 2004;172(6):3793–3797.
49. Wilson ME, Innes DJ, Sousa AD, Pearson RD. Early histopathology of experimental infection with *Leishmania donovani* in hamsters. *The Journal of Parasitology* 1987;73(1):55–63. [PubMed: 3572666]
50. Yao C, Leidal KG, Brittingham A, Tarr DE, Donelson JE, et al. Biosynthesis of the major surface protease GP63 of *Leishmania chagasi*. *Molecular and Biochemical Parasitology* 2002;121(1):119–128. [PubMed: 11985868]

Figure 1. Survival of *L. donovani* $lpg2^-$ mutants or controls in mice. A–B Female BALB/c mice were infected i.v. with 10^7 WT (●), $lpg2^-$ (○), or $lpg2^-/+LPG2(e)$ (▲) stationary phase promastigotes. Parasite loads in the spleen (**panel A**) or liver (**panel B**) were quantified microscopically. Shown is a representative of three replicate experiments; values represent the mean $\pm$ SEM for six mice at each time point. (C–D) Female BALB/c mice were infected with 10^7 stationary phase WT (open bars) or $lpg2^-$ promastigotes as above (cross-hatched bars), or with the same number of $lpg2^-/+LPG2(e)$ (black bars, **panel C**) or $lpg2^-/+LPG2(i)$ (black bars, **panel D**) add back organisms. After four weeks, mice were euthanized and parasites loads were quantified microscopically. Statistical analyses compared parasite loads in mice infected with both controls to mice infected with $lpg2^-$ organisms.

Figure 2. Survival of *lpg2*⁻ *L. donovani* in murine bone marrow macrophages

Macrophages were synchronously infected with opsonized promastigotes at a 5:1 MOI for 30 min before rinsing to remove extracellular parasites. At the indicated time points, infection levels were quantified by light microscopy. Values represent the mean $\pm$ SE for three experiments, each with triplicate conditions. Panel **A**, percent of macrophages infected; Panel **B**, the number of parasites per 100 macrophages. Cell lines tested were WT (●), *lpg2*⁻ (○), *lpg2*⁻/+LPG2(i) (▼), or *lpg2*⁻/+LPG2(e) (△).

Figure 3. PG levels in *lpg2⁻* mutants and controls

Whole cell extracts from the indicated lines grown either as promastigotes (panel A) or *in vitro* amastigotes (panel B) were subjected to western blot analysis with antiserum CA7AE which detects unmodified PG repeats (Tolson et al. 1989). Blots were re-probed with 1:1000 antibody to β -tubulin as a loading control. The migration of LPG and PPGs are as indicated in the figure. AB(b) and AB(a) refer to *lpg2⁻/+LPG2(i)* parasites harvested “before” or “after” infections.

Figure 4. Glycoconjugates in WT, *lpg2*⁻, or *lpg2*⁻/*LPG2*(i) *L. donovani* promastigotes
Parasites were recovered after 12 weeks of infection and grown as promastigotes. (A) Cytoplasmic mannans from wild type and mutant *L. donovani* separated by FACE are shown. (B) Lysates from wild type (WT), *lpg2*⁻, or *lpg2*⁻/*LPG2*(i) lines were analyzed in immunoblots probed with polyclonal anti-GP63 antisera or CA7AE anti-PG monoclonal antibody.

Figure 5. Complement sensitivity of *lpg2*⁻ mutants

The complement sensitivity of WT or *lpg2*⁻ mutants, of *L. major*, *L. mexicana*, or *L. donovani*, was measured as described in the Methods, and lysis measured by quantitation of the uptake of propidium iodide and flow cytometry. The X axis depicts propidium iodide uptake and the Y axis depicts cell numbers. Parasites were tested in logarithmic or stationary phase of growth as indicated.

Figure 6. *LPG2* expression correlates with depressed respiratory response in phagocytes
 Human peripheral blood monocytes were infected for 10 min with the CFSE-labeled WT, *lpg2*⁻ or *lpg2*⁻/ + *LPG2*(i) promastigotes, and oxidant production was detected after additional 10 minute incubation with DHE (described in the Methods section). Monocytes are gated based upon CD14 staining and forward-side scatter characteristics and infected monocytes were discerned by positive CFSE stain. The average $\pm$ standard deviation mean fluorescent intensity for DHE stain in infected monocytes, calculated from three separate experiments, is shown.

Figure 7. LPG2 expression correlates with delayed lysosomal fusion

Murine bone marrow macrophage were infected with CFSE-labeled WT, *lpg2*⁻, *lpg2*⁻/+LPG2 (*e*), or *lpg2*⁻/+LPG2(*i*) promastigotes. Control macrophages were pulsed at time 0 with GFP-labeled dextran which traffics to lysosomes. Two and 24 hours later, samples were fixed and stained with a blue LAMP-1 marker. Shown are example micrographs from the 2 hours time point. Arrows show merged blue-green signals. Arrowheads indicate green parasites that have not merged with the LAMP-1 positive marker.

Figure 8. Quantitative measurement of the delay in lysosomal fusion

Micrographs from the experiment illustrated in Figure 7 were classified by a blinded observer for fusion with lysosomes or lack of fusion. The “fusion index” was calculated as the ratio of parasites in vacuoles fused with lysosomes divided by total parasites X 100. Data were derived from at least 200 macrophages for each parasite type.